A 20-Year Real-World Benchmark of Metastatic Uveal Melanoma Outcomes in a Tebentafusp-Inaccessible Setting: A Comprehensive Cancer Center Study
Cancers · 31.10.2026 · 18 (21) · 3512
DOI: 10.3390/cancers18213512 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 31.10.2026. Verfasst von Yacob Saleh und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, King Hussein Cancer Center, Amman 11181, Jordan. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Uveal melanoma (UM) is a rare malignancy. Despite effective local control, 10–50% of patients develop metastatic disease, which is associated with poor prognosis. Real-world data remain lacking. This study evaluated the clinical characteristics, treatment patterns, and survival outcomes of metastatic UM in a comprehensive cancer center in Jordan.
Methods
This retrospective study included adult patients with metastatic UM treated and followed at King Hussein Cancer Center in Jordan (2006–2025). Baseline characteristics and treatment patterns were collected. Descriptive and inferential statistical analyses were performed in JASP v0.95.4 and R v4.5.3. A two-sided p < 0.05 was considered statistically significant.
Results
Among 125 patients with followed UM, 31 (24.8%) had metastatic disease and were included in the analysis. Median age at diagnosis was 51 years, 61.3% were males, 61.2% had an ECOG PS 0–1, and 51.6% had hepatic-only metastases. Median time to distant metastasis was 25 months. Median OS from initial diagnosis was 35 months, while median post-metastatic OS (PM-OS) was 10 months. First-line immunotherapy was associated with improved PM-OS compared to Dacarbazine (median, 11 vs. 5 months; p = 0.034; 24-month PM-OS, 44.4% vs. 0%). In exploratory analysis, patients who continued immunotherapy beyond radiologic progression, consistent with pseudoprogression, had longer PM-OS than those who discontinued therapy (median, 32 vs. 6 months; Log-rank p = 0.020).
Conclusions
In this real-world cohort, metastatic UM was associated with poor outcomes and limited access to novel therapies including Tebentafusp. First-line immunotherapy may be associated with favorable survival outcomes, and hypothesis-generating exploratory analysis suggested potential benefit from immunotherapy continuation beyond radiologic progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, King Hussein Cancer Center, Amman 11181, Jordan.
- Faculty of Medicine, University of Jordan, Amman 11942, Jordan.
- Department of Surgery (Ophthalmology), King Hussein Cancer Center, Amman 11181, Jordan.
- Department of Radiation Oncology, King Hussein Cancer Center, Amman 11181, Jordan.
- Department of Pathology, King Hussein Cancer Center, Amman 11181, Jordan.
ORCID-Profile: Yacob Saleh, Baker Shiha, Mona Mohammad, Ramiz Abuhijlih, Abdulla Alzibdeh, Yacoub A Yousef
Zitieren
APA
Saleh, Y., Shiha, B., Abu Awwad, M., Zayed, A., Hamad, M., AlNawaiseh, I., Mohammad, M., Yasir, S., Abuhijlih, R., Asha, W., Jaradat, I., Alzibdeh, A., Jaber, O., & Yousef, Y. A. (2026). A 20-Year Real-World Benchmark of Metastatic Uveal Melanoma Outcomes in a Tebentafusp-Inaccessible Setting: A Comprehensive Cancer Center Study. Cancers, 18(21), 3512. https://doi.org/10.3390/cancers18213512
Vancouver
Saleh Y, Shiha B, Abu Awwad M, Zayed A, Hamad M, AlNawaiseh I, et al. A 20-Year Real-World Benchmark of Metastatic Uveal Melanoma Outcomes in a Tebentafusp-Inaccessible Setting: A Comprehensive Cancer Center Study. Cancers. 2026;18(21):3512. doi:10.3390/cancers18213512
BibTeX
@article{Saleh2026,
author = {Saleh, Yacob and Shiha, Baker and Abu Awwad, Manar and Zayed, Anas and Hamad, Maen and AlNawaiseh, Ibrahim and Mohammad, Mona and Yasir, Sameer and Abuhijlih, Ramiz and Asha, Wafa and Jaradat, Imad and Alzibdeh, Abdulla and Jaber, Omar and Yousef, Yacoub A},
title = {A 20-Year Real-World Benchmark of Metastatic Uveal Melanoma Outcomes in a Tebentafusp-Inaccessible Setting: A Comprehensive Cancer Center Study},
journal = {Cancers},
year = {2026},
volume = {18},
number = {21},
pages = {3512},
doi = {10.3390/cancers18213512}
}
EUVIMED